Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TPMT | P51580 | 1/20 | 0.40 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | GSK3B | P49841 | 4/20 | 0.35 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.35 |
| ▸ | ACLY | P53396 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.33 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.33 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.33 |
| ▸ | FEN1 | P39748 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | FABP4 | P15090 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1448228 | 0.85 | TPMT (0.54) | TPMTRAB9AGSK3BHCAR1ERCC5 | |
| SCHEMBL2070727 | 0.85 | GSK3B (0.38) | RAB9AGSK3BALDH1A1HPGDKMT2A | |
| SCHEMBL5050069 | 0.84 | GSK3B (0.53) | TPMTGPR139RAB9AGSK3BHCAR1 | |
| SCHEMBL19137597 | 0.84 | GPR139 (0.42) | TPMTGPR139RAB9AGSK3BHCAR1 | |
| SCHEMBL29334169 | 0.84 | GSK3B (0.50) | TPMTGPR139RAB9AGSK3BHCAR1 | |
| SCHEMBL16581103 | 0.82 | TPMT (0.39) | TPMTGPR139RAB9AGSK3BHCAR1 | |
| SCHEMBL19137592 | 0.81 | HSD17B3 (0.44) | TPMTGPR139RAB9AALDH1A1HPGD | |
| SCHEMBL6175732 | 0.78 | POLB (0.44) | TPMTALDH1A1HPGDKMT2A | |
| SCHEMBL6175642 | 0.78 | TPMT (0.64) | TPMTRAB9AHCAR1ALDH1A1HPGD | |
| SCHEMBL2171006 | 0.77 | TPMT (0.44) | TPMTGPR139RAB9AHCAR1ACLY |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114751870-B | 2- (isoxazole-5-yl) phenyl-3, 4-dihydroxybenzoate and derivative thereof, and synthetic method and application thereof | 贵州医科大学 | 2023-10-20 | — | — | CN | claimed |
| CN-114751870-A | 2- (isoxazole-5-yl) phenyl-3, 4-dihydroxy benzoate and derivative thereof, and synthesis method and application thereof | 贵州医科大学 | 2022-07-15 | — | — | CN | claimed |
| US-20080254130-A1 | Skin Antiaging & Brightening via Multi-function Treatment of Enzyme Dysfunction | BIODERM RESEARCH (US) | 2008-10-16 | — | — | US | claimed |
| US-20060269494-A1 | New Ubiquitin-Proteasome Regulating Compounds and Their Application in Cosmetic and Pharmaceutical Formulations | GUPTA SHYAM K | 2006-11-30 | — | — | US | claimed |
| US-20060110415-A1 | Topical Delivery System for Cosmetic and Pharmaceutical Agents | BIODERM RESEARCH (US) | 2006-05-25 | — | — | US | claimed |
| US-20060074108-A1 | Matrix metalloprotease (MMP) inhibitors and their application in cosmetic and pharmaceutical composition | BIODERM RESEARCH (US) | 2006-04-06 | — | — | US | claimed |
| US-20050271608-A1 | Skin whitening compositions based on hydroxyaryl alkyl ketones and their isosteric derivatives | GUPTA SHYAM K | 2005-12-08 | — | — | US | claimed |
| WO-2023205439-A2 | SKIN BARRIER PROTECTIVE DELIVERY SYSTEMS AND METHODS THEREOF | BOBO LABS INC. (US) | 2023-10-26 | — | — | WO | disclosed |
| CN-114751870-B | 2- (isoxazole-5-yl) phenyl-3, 4-dihydroxybenzoate and derivative thereof, and synthetic method and application thereof | 贵州医科大学 | 2023-10-20 | — | — | CN | disclosed |
| CN-115010688-A | One-pot preparation method of 4-chromanone, congeners and derivatives thereof | 烟台六谛医药科技有限公司 | 2022-09-06 | — | — | CN | disclosed |
| CN-114751870-A | 2- (isoxazole-5-yl) phenyl-3, 4-dihydroxy benzoate and derivative thereof, and synthesis method and application thereof | 贵州医科大学 | 2022-07-15 | — | — | CN | disclosed |
| US-7910742-B2 | Survivin inhibitors | ABBOTT LABORATORIES (US) | 2011-03-22 | — | — | US | disclosed |
| US-20090130154-A1 | Topical Delivery of Biological and Cosmetic Agents by Zeolites | BIODERM RESEARCH (US) | 2009-05-21 | — | — | US | disclosed |
| US-20080254130-A1 | Skin Antiaging & Brightening via Multi-function Treatment of Enzyme Dysfunction | BIODERM RESEARCH (US) | 2008-10-16 | — | — | US | disclosed |
| US-20080139507-A1 | Method of Treating Skin Condition Including Acne, Skin Aging, Body Odor & Diaper Rash by Zinc Zeolite Clathrates | BIODERM RESEARCH (US) | 2008-06-12 | — | — | US | disclosed |
| US-20070072833-A1 | Survivin inhibitors | ABBVIE INC. | 2007-03-29 | — | — | US | disclosed |
| US-20060269494-A1 | New Ubiquitin-Proteasome Regulating Compounds and Their Application in Cosmetic and Pharmaceutical Formulations | GUPTA SHYAM K | 2006-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072833-A1 | Survivin inhibitors | XIAP, BIRC5, BIRC3 | TPMT 3717/4885GPR139 4234/4885RAB9A 2539/4885 |
| US-20090130154-A1 | Topical Delivery of Biological and Cosmetic Agents by Zeolites | TYR, MMP1, MMP17 | TPMT 4391/4885GPR139 3170/4885RAB9A 4282/4885 |
| US-20080254130-A1 | Skin Antiaging & Brightening via Multi-function Treatment of Enzyme Dysfunction | PSMB1, PLOD3, CUTA | TPMT 4213/4885GPR139 4670/4885RAB9A 2999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.